title: Enhancement of bone ingrowth by transforming growth factor-beta.
abstract: Enhancement of bone ingrowth with transforming growth factor-beta was evaluated in a canine model. Ten dogs had bilateral implantation of a titanium-fiber-metal-coated rod in the proximal part of the humerus. A three-millimeter gap between the outer surface of the porous coating and the surrounding cancellous bone was created to impair bone ingrowth. All of the implants were plasma-flame-sprayed with hydroxyapatite and tricalcium phosphate. In each animal, one implant was also treated with recombinant transforming growth factor-beta 1 while the other implant, which was not so treated, served as a paired control. Two doses of transforming growth factor-beta 1 were used: 335 micrograms in five animals and 120 micrograms in the other five. At four weeks, the amount of bone ingrowth in the implants that had been treated with 120 micrograms of transforming growth factor-beta 1 was threefold higher than that in the paired controls (p = 0.009), but with the numbers available there was no significant increase in bone ingrowth with the higher dose. The amount of new-bone formation in the three-millimeter gaps adjacent to the treated implants was twice that in the gaps of the paired controls, regardless of the dose. The differences between the treated and control implants with regard to the architecture of the new bone in the gap indicate that the mechanism of action of transforming growth factor-beta 1 may include both proliferation of osteoprogenitor cells and production of matrix by committed osteoblasts. Compared with the findings in a previous study in which this canine model was used, the data from the present investigation indicate that enhancement of bone ingrowth in implants that have been treated with a combination of a hydroxyapatite-tricalcium phosphate coating and transforming growth factor-beta 1 may exceed that obtainable with grafting of the gap with autogenous cancellous bone.
authors.affiliation: Department of Orthopedic Surgery, Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois 60612, USA.
authors.forename: D R
authors.initials: DR
authors.lastname: Sumner
authors.forename: T M
authors.initials: TM
authors.lastname: Turner
authors.forename: A F
authors.initials: AF
authors.lastname: Purchio
authors.forename: W R
authors.initials: WR
authors.lastname: Gombotz
authors.forename: R M
authors.initials: RM
authors.lastname: Urban
authors.forename: J O
authors.initials: JO
authors.lastname: Galante
mesh_terms: D000818:Animals; D001858:Bone Nails; D002130:Calcium Phosphates; D004285:Dogs; D017886:Durapatite; D006811:Humerus / Q000601:surgery / Q000648:ultrastructure; D008297:Male; D008855:Microscopy, Electron, Scanning; D016348:Osseointegration / Q000187:drug effects*; D011994:Recombinant Proteins / Q000494:pharmacology; D013997:Time Factors; D014025:Titanium; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
chemical_list: D002130:Calcium Phosphates; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C485828:alpha-tricalcium phosphate; C485830:tetracalcium phosphate; C485838:calcium phosphate, monobasic, anhydrous; D017886:Durapatite; C020243:calcium phosphate; D014025:Titanium; C485829:calcium phosphate, dibasic, anhydrous